


### PHARMACEUTICAL 2022

## Zentalis Pharmaceuticals Inc. Rank 186 of 466









#### PHARMACEUTICAL 2022

# zentalis

# Zentalis Pharmaceuticals Inc. Rank 186 of 466

The relative strengths and weaknesses of Zentalis Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zentalis Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 30% points. The greatest weakness of Zentalis Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 171%, being 93% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	350,770
Cost of Goods Sold	0
Intangible Assets	3,736
Liabilities, Current	43,944
Liabilities, Non-Current	44,459
Other Assets	91,853
Other Compr. Net Income	7,207
Other Expenses	-297
Other Liabilities	1,622
Other Net Income	50,152
Other Revenues	0
Property and Equipment	8,148
Research and Development	175,601
Selling, General and Administrative Expense	40,941

Output Variable	Value in 1000 USD
Assets	454,507
Liabilities	90,025
Expenses	216,245
Revenues	0
Stockholders Equity	364,482
Net Income	-166,093
Comprehensive Net Income	-162,490
Economic Capital Ratio	171%

